Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised
PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.
S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks
Major U.S. equities indexes pulled back from their early gains Friday as investors wait for new developments on tariffs ahead of a weekend meeting between U.S. and Chinese officials.
Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director, IR Tim Scannell - Chair Ashley McEvoy - President and CEO Ana Chadwick - EVP and CFO Eric Benjamin - Chief Product and Customer Experience Officer Conference Call Participants Travis Steve - Bank of America Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Patrick Wood - Morgan Stanley Marie Thibault - BTIG Michael Polark - Wolfe Research Matt O'Brien - Piper Sandler Steve Lichtman - Oppenheimer Issie Kirby - Redburn Atlantic Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation First Quarter Earnings Call. At this time, all participants are in a listen-only mode.
Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates
Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago.
Insulet beats quarterly profit estimates on insulin pump demand
Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.
Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Insulet Names New CEO, Expects to Top Revenue Projections
Insulet (PODD) shares edged lower Monday as the maker of an insulin delivery device for diabetes patients announced a shakeup in its leadership.
PODD Stock Benefits From the Launch of Omnipod 5 in Canada
Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.
Insulet Gains 62.9% in a Year: What's Driving the Stock?
PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.
PODD Stock Gains Following the Launch of Omnipod 5 in Australia
Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.
